Ibrahim, F., soliman, M., Elsaied, H. (2023). Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients. test, 2(1), 59-69. doi: 10.21608/ijtar.2023.141826.1009
Fathia Ahmed Ibrahim; maha ghazi soliman; Hanaa Hanaa Abdelfattah Elsaied. "Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients". test, 2, 1, 2023, 59-69. doi: 10.21608/ijtar.2023.141826.1009
Ibrahim, F., soliman, M., Elsaied, H. (2023). 'Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients', test, 2(1), pp. 59-69. doi: 10.21608/ijtar.2023.141826.1009
Ibrahim, F., soliman, M., Elsaied, H. Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients. test, 2023; 2(1): 59-69. doi: 10.21608/ijtar.2023.141826.1009

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

International Journal of Theoretical and Applied Research
Volume 2, Issue 1, June 2023, Pages 59-69    PDF (467.95 K)
Document Type: Review articles
DOI: 10.21608/ijtar.2023.141826.1009
Authors
Fathia Ahmed Ibrahim* 1; maha ghazi soliman2; Hanaa Hanaa Abdelfattah Elsaied3
1Zoology, faculty of science al-azhar university,cauro, Egypt
2zoology-entomology, faculty of science, al-azhar university, Cairo, Egypt
3medical microbilogy ,National organization for drug control and research, cairo, egypt
Abstract
Hepatic, renal, and immune system impairment are associated with chronic hepatitis C virus (HCV) infection. This study looked at how some hepatic and renal functions in HCV patients were impacted by treatment with direct acting antivirals (DAAs). Six hundred male and female Egyptian patients with HCV infection who received three months of sofosbuvir/daclatasvir combined therapy and were primarily identified by anti-HCV antibodies were prospectively enrolled. This study measured peripheral blood hematological parameters, pre- and post-treatment serum HCV RNA viral load, alpha-fetoprotein, ALT, AST, total bilirubin, creatinine, and other parameters. Three months of sofosbuvir/daclatasvir combined therapy resulted in SVR in 100% of patients. Blood hemoglobin, platelets count, neutrophils%, and eosinophil% were all significantly higher after treatment, whereas post-treatment HCV RNA viral load, alpha-fetoprotein ALT, AST, total bilirubin, creatinine, total leucocyte count, lymphocytes percent, and monocytes percent were all significantly lower. This study's findings suggest that DAAs sofosbuvir/daclatasvir combined therapy for three months has a significant impact on biochemical, immunological, and hematological parameters, suggesting clinically significant findings in patients with CHC who have been successfully treated.
Keywords
sovaldi; daclatsvir; immmunobiochemical
Statistics
Article View: 367
PDF Download: 215